Key result
Magnetic resonance imaging is at least five times more sensitive to disease activity and approximately twice as sensitive to treatment effects than clinical measurements in multiple sclerosis.
Why the study?
Does magnetic resonance imaging (MRI) provide greater sensitivity to disease activity and treatment effects compared to clinical measurements in multiple sclerosis clinical trials?
Does magnetic resonance imaging (MRI) provide greater sensitivity to disease activity and treatment effects compared to clinical measurements in multiple sclerosis clinical trials?
MRI is a highly sensitive, objective method for evaluating disease activity and treatment effects in multiple sclerosis clinical trials.
MRI may enhance multiple sclerosis trial sensitivity; leaves open prospective validation against clinical outcomes.
Magnetic resonance imaging (MRI) provides an objective method of evaluating multiple sclerosis clinical trials and is at least five times more sensitive to disease activity. In a recent clinical trial, MRI was also approximately twice as sensitive as clinical measurements to the treatment effect of a drug.
No takes yet. Share an insight, caveat, or question.
Paty et al. (1994) studied this question. Magnetic resonance imaging is at least five times more sensitive to disease activity and approximately twice as sensitive to treatment effects than clinical measurements in multiple sclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: